Breaking Down SG&A Expenses: Incyte Corporation vs Viatris Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Incyte Corporation and Viatris Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Incyte's SG&A expenses have surged by approximately 600% over this period, reflecting its aggressive expansion and investment in operational capabilities. Meanwhile, Viatris Inc., formed in 2020 through the merger of Mylan and Upjohn, has maintained a more stable trajectory, with a 210% increase in SG&A expenses, indicating a focus on consolidation and efficiency.

By 2023, Viatris's SG&A expenses were nearly four times those of Incyte, highlighting its larger scale and broader market reach. This comparison offers a fascinating glimpse into how different strategic priorities manifest in financial outcomes, providing valuable insights for investors and industry analysts alike.